Scivita Medical enters into Strategic Agreement with Boston Scientific in China

SUZHOU, China, March 29, 2023 /PRNewswire/ — Medical technology company Scivita Medical Technology Co., Ltd. (‘Scivita Medical’) and Boston Scientific (NYSE: BSX), one of the leading medical technology companies worldwide, have officially signed a Strategic Agreement for Scivita’s Single-Use Percutaneous Choledochoscope. Through this business cooperation and distribution agreement, Scivita Medical and Boston Scientific plan to establish a long-term partnership in the commercialization, marketing and promotion of Scivita’s Single-Use Percutaneous Choledochoscope in China.


Signing ceremony

Under Scivita Medical’s comprehensive product lineup of reusable endoscopes, single-use videoscopes and related systems and equipment, this cooperation further broadens its market penetration of its Single-Use Percutaneous Choledochoscope. Through the strong alliance with Boston Scientific, the penetration rate of the Single-Use Percutaneous Choledochoscope in China is expected to increase benefiting more hospitals and patients.


Single-Use Percutaneous Choledochoscope

Scivita Medical said, ‘Thanks to Boston Scientific for its recognition of Scivita Medical. This is another important initiative for Scivita Medical in establishing its vision of becoming a global company, and another milestone following its strategic cooperation with Fujifilm for the European market. I believe this strategic cooperation with some of the world’s leading medical technology companies and our company will accelerate the process of bringing China’s medical innovations to the world.’

As a result of the growing demands of mitigating the risks of cross-contamination and hospital-acquired diseases, particularly amid the outbreak of COVID-19 pandemic, the global single-use videoscope market is also rapidly growing. The global market value of single-use videoscope was USD 0.5 billion in 2020, and is estimated to increase to USD 9.2 billion in 2030, according to Frost & Sullivan. Scivita Medical’s single-use videoscopes have covered multiple clinical departments at a high risk of cross-infection, such as Gynecology, Respiratory, Urological Surgery and Hepatobiliary Surgery. Many of its products have already been approved in China, the United States, European Union (EU), Japan and other countries and regions.


Scivita Medical New Plant

This cooperation can be seen as strong evidence of Scivita Medical’s comprehensive product lineup of reusable endoscopes, single-use videoscope and related systems and equipment, which further accelerates its commercialization and penetration in the field of single-use videoscope. In the future, Scivita Medical will further strengthen its innovation, improve market penetration by offering unique products and strive to become the preferred brand for doctors and patients worldwide.

About Scivita Medical

Founded in 2016, Scivita Medical is a medical device company that provides minimally invasive diagnosis and treatment solutions, and focuses on research, development and commercialization of medical endoscopes and related products. Scivita Medical takes ‘Globalization’ as its core strategy and has established R&D centers both in China and Japan. With solid in-house R&D capabilities, Scivita Medical has established a unique technology platform built upon five synergistic core technologies, and built a comprehensive portfolio of endoscope products and therapeutic products covering all types of endoscope procedures conducted by the various clinical departments, to address diverse medical needs. Adhering to its value of ‘Clinical Focus’ ‘Collaborative Innovation’ ‘People Oriented’ ‘Excellence & Efficiency’, Scivita Medical will continuously upgrade its core technologies, improve market penetration with excellent products aiming to become the preferred brand, trusted by doctors and patients around the world.

For more information, please visit: scivitamedical.com/#/ 

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.